Tourmaline Bio, Inc. (NASDAQ:TRML) Receives $61.80 Average Target Price from Brokerages

Tourmaline Bio, Inc. (NASDAQ:TRML – Get Free Report) has received a consensus rating of “Buy” from the six ratings firms that are covering the firm, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy recommendation. The average 12 month target price among brokerages that have issued a report on the stock […]

Related Keywords

Mark Mcdade ,Jefferies Financial Group ,Nasdaq ,Capital Management ,Denali Advisors ,Affinity Asset Advisors ,Tourmaline Bio Company Profile ,Tourmaline Bio Inc ,Securities Exchange Commission ,Jump Financial ,Tourmaline Bio ,Get Free Report ,Marketbeat Ratings ,Director Mark Mcdade ,Exchange Commission ,Asset Advisors ,Get Free ,Tourmaline Bio Daily ,